Stukinase 1500000IU Injection is a medication classified as an antifibrinolytic agent. It is primarily used to dissolve blood clots that have formed in the blood vessels. The active ingredient in Stukinase 1500000IU Injection is Streptokinase, which forms a specific enzymatic complex with plasminogen, converting inactive plasminogen molecules into active plasmin. Plasmin is responsible for breaking down fibrin clots in the blood, ultimately leading to the dissolution of blood clots.

This medication is typically utilized in various medical conditions such as intravascular dissolution of thrombi and emboli in extensive deep vein thrombosis, pulmonary embolism, acute or subacute occlusion of peripheral arteries, central retinal venous and arterial thrombosis. Stukinase 1500000IU Injection should only be administered to patients within a hospital setting by a skilled healthcare provider due to its potent effects on blood clot dissolution.

It is essential for patients to be aware of potential side effects associated with Stukinase 1500000IU Injection. Common side effects may include allergic reactions, variations in blood pressure and heart rate, gastrointestinal issues like nausea and vomiting, as well as other symptoms like headaches and musculoskeletal pain. These side effects are generally temporary and tend to resolve on their own. However, if any severe side effects, such as vision problems, occur while using Stukinase 1500000IU Injection, immediate medical consultation is advised.

Stukinase 1500000IU Injection is approved for adult use, and its safety and efficacy have not been established for individuals under 18 years old. Patients should inform their healthcare provider if they are pregnant, planning for pregnancy, or breastfeeding, as Stukinase 1500000IU Injection is contraindicated during pregnancy, particularly within the first 18 weeks. The excretion of Streptokinase in human milk is unknown, thus breastfeeding should be avoided within the first 24 hours following thrombolytic therapy to prevent any potential risks.

Patients undergoing treatment with Stukinase 1500000IU Injection should ensure they inform their healthcare provider of any pre-existing bleeding disorders, kidney or liver diseases, as well as all other medications they are currently taking to prevent any potential interactions or complications. It is crucial to carefully follow the dosage and administration instructions provided by the doctor and to continue any other long-term medications as advised for overall treatment management.